Naviscan completes enrollment for PEM trial

12/21/2008 | (free registration)

PET developer Naviscan has finished patient enrollment for a study that would compare the sensitivity and specificity of positron emission mammography and breast MRI. The trial also aims to evaluate PEM's potential to affect patient-management options. The firm also recently attained FDA clearance for its surgical-navigation software, which is scheduled for beta testing in the next few months.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care